China health app starts online sales of Pfizer's Paxlovid for COVID treatment (updated)
13/12/2022 09:34
(Adds details)
BEIJING, Dec 13 (Reuters) - A Chinese healthcare
platform has started selling Pfizer's PFE.N oral COVID
treatment pill Paxlovid in what appears to be the first retail
sale of the drug in the country, as China braces for a surge in
COVID patients.
Healthcare company 111.inc has started selling Paxlovid
for 2,980 yuan ($426.80) per box, the sales page on the app
showed on Tuesday.
People can purchase the medication on the app if they submit
a positive COVID-19 test result.
Chinese media Yicai reported in March that Paxlovid,
which was approved by China in February, has been used to treat
high-risk patients in hospitals in at least eight provinces.
($1 = 6.9822 Chinese yuan renminbi)
(Reporting by Beijing newsroom; Editing by Andrew Heavens and
Kim Coghill)
((Albee.Zhang@thomsonreuters.com;))